Theoretical and clinical equipoise in medical research

A doctor should give a patient the best available treatment. That sounds straightforward until the doctor is also comparing treatments in a study. Different groups receive different treatments, so some patients don't receive a treatment that others receive. How can the researcher do that while honoring the obligation to give the best care?

Picture one group receiving an accepted treatment and another receiving a new one. The comparison needn't leave either group entirely untreated. Even so, the doctor is withholding one available option from each group. Which should each patient receive if the doctor already thinks one is better?

The traditional answer is equipoise: the participating physician should have no opinion about which treatment is clinically superior. The author calls the usual strict version theoretical equipoise. Each researcher must judge the overall evidence for the two treatments to be exactly balanced. That is a requirement about researchers' assessment of evidence, not a finding that the treatments actually have identical effects.

Picture comparing an established cancer treatment with a promising new one. A researcher may favor the established option because it has a longer track record; another may find the new evidence more compelling. How often will every participating researcher have no preference at all? Even a small preference is a problem for a standard demanding exact balance.

There is a second difficulty. Suppose the researchers do begin without a preference. As results arrive, a little new evidence could tip someone's judgment. The strict balance would then be lost before the study is complete. The author isn't giving us a tally of trials that have actually been stopped. This is an explanation of what consistently applying such a fragile standard would permit: few trials could begin, and fewer could finish.

So the author proposes clinical equipoise. The goal is to preserve rigorous ethical standards without imposing an unreasonable obstacle to research. The key change is where we look for the unresolved issue: not inside every individual researcher's perfectly balanced mind, but across the relevant expert community.

Return to the cancer-treatment example. Some experts may favor the established treatment, while others consider the new one more promising. Both sides can recognize that their opponents have honest reasons for interpreting the evidence differently. A trial could help resolve that real disagreement. Having a preference doesn't automatically make a researcher incapable of conducting an ethical comparison.

The last paragraph makes the safeguard concrete. Each researcher must recognize that a sizable group of medical professionals favors the treatment that researcher likes less. Clinical equipoise therefore isn't permission to test anything merely because someone wants to. The less-favored treatment needs meaningful support within the profession. Nor does it require the participating researchers themselves to divide into equal camps.

That distinction connects the proposed solution to the original problem. A doctor can prefer treatment A while acknowledging that a substantial expert constituency reasonably prefers B. Under clinical equipoise, that preference alone doesn't bar participation; under theoretical equipoise, it disrupts the required individual balance.

Our main point is a recommendation with a reason: replace theoretical equipoise with clinical equipoise because the latter maintains an ethical standard while avoiding the former's unreasonable restrictions on comparative trials. Defining two terms is part of the work, but the author is choosing between them.